drugset / Trial / NCT05664139
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
Phase 2
Unknown
30 enrolled
Fujian Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd. · collabSunWay Biotech Co., LTD. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is the first to explore the efficacy and safety of recombinant human adenovirus type 5 injection combined with PD-1 monoclonal antibody and nab-paclitaxel in the treatment of patients with liver metastases of melanoma, in order to provide a new method for the clinical treatment of melanoma. The model also provides reference and basis for other tumor treatments.
Timeline
- Start
- 2023-02
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Recombinant Human Adenovirus Type 5 Injection | Unknown | 1 ml | Other |
| Subject | Recombinant Human Adenovirus Type 5 Injection | Unknown | 2 ml | Other |